GlaxoSmithKline poached Pfizer's RNA and viral vaccines leader Phil Dormitzer, M.D., Ph.D., to shore up its vaccine business as it's lost many research staffers this past year. Parthenon Therapeutics snagged Johnson & Johnson's global head of cell therapy platform and discovery, Tamas Oravecz, Ph.D. And Rafael parted ways with five execs and reinstalled telecom tycoon Howard Jonas as CEO.